Ironsides Asset Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Ironsides Asset Advisors’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-14,550	Closed	-$619K	–	96
2017 Q3	$619K	Sell	14,550 -14,950	-51%	-$634K	0.25%	49
2017 Q2	$1.27M	Buy	+29,500	New	+$1.24M	0.55%	23
2017 Q1	–	Sell	-70,550	Closed	-$2.76M	–	147
2016 Q4	$2.76M	Buy	+70,550	New	+$2.87M	0.75%	29

Other funds holding XPH

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

Ironsides Asset Advisors's XPH Position: Q4 2017 in Review

Ironsides Asset Advisors sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q4 2017, closing a stake of 14,550 shares — an estimated $619K sold.

Ironsides Asset Advisors first reported a position in XPH in Q4 2016 and held it in 3 quarters. The position peaked at $2.76M in Q4 2016. 85 funds tracked by Wall St. Rank hold XPH as of Q4 2017.

Ironsides Asset Advisors reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q4 2017 after selling out during the quarter.
Ironsides Asset Advisors sold 14,550 State Street SPDR S&P Pharmaceuticals ETF shares in Q4 2017, an estimated $619K.
Ironsides Asset Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2016 and held it in 3 quarters.
Ironsides Asset Advisors's State Street SPDR S&P Pharmaceuticals ETF position peaked at $2.76M in Q4 2016.
85 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2017.

Based on Ironsides Asset Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.